Skip to main content
Glama

Jpl Ssd

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

Schema Changelog

Changes observed during successful MCP inspections. Dates show when Glama detected each change.

  1. Changed1 schema field changed
    • changedInput schema / properties / value / description
      Previous value: -"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\")."New value: +"For company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., \"ozempic\", \"metformin\"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed (\"NEW YORK ST DORM AUTH\"), never the question's full noun phrase (\"NEW YORK ST DORM AUTH revenue bonds\"): the FIGI lookup matches instrument names, so trailing security-class words match nothing."
  2. First observed

TDQS

A4/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

The description goes well beyond the annotations by explaining ambiguous-name behavior ('asserts nothing and returns figi_candidates'), graceful degradation ('if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return'), internal cascading lookups, and explicit handling of unresolved identifiers under `unresolved`. This gives the agent a strong behavioral model before invoking the tool.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness2/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The tool description is a single sprawling paragraph with nested parentheticals, long em-dash chains, and overlapping caveats. While the content is valuable, it is not appropriately structured or concise; bulleted or sectioned presentation would make it far more scannable for an agent.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a complex two-type resolution tool with no output schema, the description covers accepted inputs, ambiguous-match behavior, source labeling, graceful degradation, and the returned identifier fields. It does not give an explicit response structure, but it supplies enough context for an agent to know what to expect.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

The schema already covers both parameters at 100%, but the description adds important accepted input not present in the schema description, such as ISIN input ('an ISIN like "CH0038863350" resolves...'). It also reinforces the drug brand/generic distinction. The bond-issuer-format guidance is already in the schema, so this is not fully additive, but the description does provide extra semantic value.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose4/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete user queries and clearly states the tool's job: 'resolve a user-spoken NAME to the canonical/official identifiers other tools require as input.' It enumerates supported types and their outputs. However, it never names sibling tools it is not, so differentiation is implicit rather than explicit.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description gives an explicit trigger condition: 'Use FIRST whenever you have a name but need an ID.' It also notes that the tool 'replaces 2-3 manual lookups,' which helps an agent decide to prefer it. It does not explicitly state when not to use it or name alternative sibling tools, so exclusions are missing.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Jpl Ssd toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.5/5.0
Disambiguation2/5

Multiple tools overlap in purpose, especially the ask_pipeworx variants and the polymarket_* tools. An agent would struggle to distinguish between similar functions, increasing the risk of selecting the wrong tool.

Naming Consistency2/5

Tool names use inconsistent conventions: some are snake_case (close_approaches), some are verb_noun (generate_llms_txt), and others mix styles (ask_pipeworx vs. deep_research). No clear pattern is maintained across the set.

Tool Count1/5

At 35 tools, the server is bloated and unfocused. The majority of tools are unrelated to the 'Jpl Ssd' domain, which only has 4 relevant tools. The count is far too high for the stated purpose.

Completeness2/5

The JPL SSD coverage is minimal (only 4 tools), missing key functionalities like detailed object queries or bulk downloads. The remaining tools cover unrelated domains, so the surface is both incomplete for its primary domain and cluttered with off-topic tools.

Resources